Scilex to spin off pharma unit

 

Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

https://www.globenewswire.com/news-release/2024/10/16/2963906/0/en/Scilex-Holding-Company-Announces-that-its-Board-of-Directors-has-Authorized-Management-to-Explore-Ways-to-Maximize-the-Value-of-its-Wholly-Owned-Subsidiary-Scilex-Pharmaceuticals-I.html